Get the latest news, insights, and market updates on MNPR (Monopar Therapeutics Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Broadcom Stock Sees Improved Relative Strength Rating
In a welcome move, Broadcom stock saw its Relative Strength Rating improve from 70 to 79 on Monday. See if Broadcom stock can continue to show renewed price strength and clear that threshold. Is Broadcom Stock A Buy? Feb 9, 2026 - $MNPR
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On September 14-15, 2025, the Company presented new data on the long-term neurological efficacy and safety of ALXN1840 (tiomolybdate choli Nov 13, 2025 - $MNPR
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presenting new data and analyses today from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025, taking place in Washington, D.C., from November 7-11, 2025. In an oral pr Nov 9, 2025 - $MNPR
Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 42.5% in Monopar Therapeutics (MNPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. Oct 21, 2025 - $MNPR
How the Narrative Around AstraZeneca Is Shifting Amid New Risks and Pipeline Developments
The consensus analyst price target for AstraZeneca has seen a slight upward revision, rising from £138.16 to £140.96, as market expectations are recalibrated. This adjustment comes amid evolving analyst perspectives that balance optimism around pipeline expansion with caution regarding competitive and patent risks. Stay tuned to discover how investors can navigate these shifting expectations and stay informed on AstraZeneca's evolving narrative. What Wall Street Has Been Saying 🐂 Bullish... Oct 18, 2025 - $MNPR
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy
Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the best hot stocks to invest in. On October 6, Raymond James raised the firm’s price target on Monopar Therapeutics to $142 from $80, while keeping a Strong Buy rating on the shares. The firm thinks that the company’s shares can continue to work well into 2026. Earlier […] Oct 16, 2025 - $MNPR
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple